Active Not RecruitingNCT06941844
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
Researchers are comparing DT120 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Medication studyAges 18–74United States
Understand this study
What is this study about?
Researchers are comparing DT120 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 14, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 149
- Sponsor
- Definium Therapeutics US, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT06941844
- Official title
Show the full official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · La Jolla · Santa Monica
17 more locations
- Denver
- Jacksonville
- Orlando
- Chicago
- Baltimore
- Boston
- Watertown
- Columbia
- Berlin
- New York
- Canton
- Cincinnati
- Philadelphia
- Memphis
- Austin
- Murray
- Bennington
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing DT120 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Definium Therapeutics US, Inc.
Does this study involve medication?
Yes. The study involves medication, including DT120.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 74 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
